While No­var­tis com­bats gener­ic on­slaught in the courts, FDA ap­proves first Gilenya copy­cats

While No­var­tis is bat­tling to weak­en the chal­lengers vy­ing to mar­ket copy­cat ver­sions of its block­buster mul­ti­ple scle­ro­sis treat­ment Gilenya — the US drug reg­u­la­tor on …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.